{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.8","upperLimit":"87.6","value":"70.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved partial response (PR) or better (VGPR) per the modified consensus response criteria from sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) (National Comprehensive Cancer Network \\[NCCN\\], 2019). PR: greater than or equal to (\\>=) 50 percent (%) reduction of serum immunoglobulin M (IgM) from baseline, with reduction in lymphadenopathy/splenomegaly if present at baseline. Very Good Partial Response (VGPR): \\>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From start of the treatment (Day 1) up to 49.3 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}